Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
substance use disorder
Biotech
Addex stock rises after Indivior offers up to $300M for compound
Indivior is picking up Addex's compound designed to treat substance use disorder, giving the Swiss biotech the chance to make up to $300 million.
Gabrielle Masson
Aug 27, 2024 10:50am
Click, Indivior to make digital therapeutics for addiction
Sep 8, 2023 1:13pm
C4X sells substance disorder drug rights to Indivior for $20M
Aug 1, 2023 7:49am
Prescription app maker Pear Therapeutics files for bankruptcy
Apr 10, 2023 10:13am
Stalicla pledges $270M for Novartis' failed fragile X asset
Jan 9, 2023 8:06am
Compound shows promise in reversing dangerous fentanyl effects
Dec 19, 2022 4:46pm
